The gut and intestinal bacteria in chronic heart failure.

Chronic heart failure (CHF) is now recognized as a multisystem disorder with increased sympathetic tone, hormonal derangements, an anabolic/catabolic imbalance, endothelial dysfunction, and systemic low-grade inflammation affecting various organ systems. Pro-inflammatory cytokines appear to play important roles in that context. There is increasing evidence for the gut to have a pathophysiological role for both chronic inflammation and malnutrition in CHF. Indeed, disturbed intestinal microcirculation and barrier function in CHF seem to trigger cytokine generation, thereby contributing to further impairment in cardiac function. On the other hand, myocardial dysfunction can induce microcirculatory injuries leading to a disruption in the intestinal barrier. This amplifies the inflammatory response. Furthermore, alterations of specific absorption functions of the intestinal mucosa in CHF may aggravate symptoms of cachexia. The increased number of adherent bacteria seen in patients with CHF and elevated systemic levels of anti-lipopolysaccharide immunoglobulin A underscore this fact. Therefore, the gut poses an interesting target for therapeutic interventions in patients with CHF.

[1]  S. Anker,et al.  Biomarkers for Chronic Heart Failure , 2009, Herz.

[2]  P. Ponikowski,et al.  Cachexia: a new definition. , 2008, Clinical nutrition.

[3]  E. Ferlin,et al.  Inspiratory muscle training improves blood flow to resting and exercising limbs in patients with chronic heart failure. , 2008, Journal of the American College of Cardiology.

[4]  R. Serov,et al.  Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure. , 2008, International Journal of Cardiology.

[5]  P. Poole‐Wilson,et al.  Fluvastatin reduces increased blood monocyte Toll-like receptor 4 expression in whole blood from patients with chronic heart failure. , 2008, International journal of cardiology.

[6]  A. Sandek,et al.  The endotoxin-lipoprotein hypothesis – an update , 2008 .

[7]  B. Corthésy,et al.  Secretory IgA Mediates Bacterial Translocation to Dendritic Cells in Mouse Peyer’s Patches with Restriction to Mucosal Compartment1 , 2007, The Journal of Immunology.

[8]  P. Ponikowski,et al.  Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. , 2007, Journal of the American College of Cardiology.

[9]  P. Poole‐Wilson,et al.  Altered intestinal function in patients with chronic heart failure. , 2007, Journal of the American College of Cardiology.

[10]  R. Neubig,et al.  Phagocyte-derived catecholamines enhance acute inflammatory injury , 2007, Nature.

[11]  R. Wojnicz,et al.  [Effect of elevated bilirubin levels on the long-term outcome in patients with chronic heart failure due to hypertension]. , 2007, Polskie Archiwum Medycyny Wewnetrznej.

[12]  Stefan Störk,et al.  Complementary and Incremental Mortality Risk Prediction by Cortisol and Aldosterone in Chronic Heart Failure , 2007, Circulation.

[13]  Stephan von Haehling,et al.  Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. , 2007, Cardiovascular research.

[14]  P. Ponikowski,et al.  Anabolic Deficiency in Men With Chronic Heart Failure: Prevalence and Detrimental Impact on Survival , 2006, Circulation.

[15]  S. Anker,et al.  The need for a standardized definition for cachexia in chronic illness , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[16]  S. Anker,et al.  Toll-like receptor modulation in cardiovascular disease: a target for intervention? , 2006, Expert opinion on investigational drugs.

[17]  S. Anker,et al.  The anti‐CD14 antibody IC14 suppresses ex vivo endotoxin stimulated tumor necrosis factor‐alpha in patients with chronic heart failure , 2006, European journal of heart failure.

[18]  P. Ponikowski,et al.  Autonomic imbalance and immune activation in chronic heart failure - pathophysiological links. , 2006, Cardiovascular research.

[19]  P. Poole‐Wilson,et al.  Cellular endotoxin desensitization in patients with severe chronic heart failure , 2005, European journal of heart failure.

[20]  O. Jolobe Jaundice as a Presentation of Heart Failure , 2005, Journal of the Royal Society of Medicine.

[21]  W. Grander,et al.  Cardiac hepatopathy before and after heart transplantation , 2005, Transplant international : official journal of the European Society for Organ Transplantation.

[22]  P. Poole‐Wilson,et al.  Effect of noradrenaline and isoproterenol on lipopolysaccharide-induced tumor necrosis factor-alpha production in whole blood from patients with chronic heart failure and the role of beta-adrenergic receptors. , 2005, The American journal of cardiology.

[23]  L. Goodnough,et al.  Anemia of chronic disease. , 2005, The New England journal of medicine.

[24]  U. Dutta,et al.  An endoscopic study of upper-GI mucosal changes in patients with congestive heart failure. , 2004, Gastrointestinal endoscopy.

[25]  D. Silverberg,et al.  The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron? , 2004, Journal of nephrology.

[26]  T. Ganz Hepcidin in iron metabolism , 2004, Current opinion in hematology.

[27]  S. Anker,et al.  Studies on intragastric PCO2 at rest and during exercise as a marker of intestinal perfusion in patients with chronic heart failure , 2004, European journal of heart failure.

[28]  S. Anker,et al.  Selective intestinal decontamination in advanced chronic heart failure: a pilot trial , 2004, European journal of heart failure.

[29]  Stephan von Haehling,et al.  Inflammatory mediators in chronic heart failure: an overview , 2004, Heart.

[30]  S. Anker,et al.  Anemia in chronic heart failure: pathogenetic mechanisms. , 2004, Journal of cardiac failure.

[31]  A. Hopkins,et al.  Proinflammatory Cytokines Disrupt Epithelial Barrier Function by Apoptosis-Independent Mechanisms 1 , 2003, The Journal of Immunology.

[32]  G. Schuler,et al.  Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure , 2003, European journal of heart failure.

[33]  S. Anker,et al.  Tumour necrosis factor-α and the failing heart , 2003, Basic Research in Cardiology.

[34]  P. Ponikowski,et al.  Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. , 2003, International journal of cardiology.

[35]  D. L. Le Couteur,et al.  Liver dysfunction and heart failure. , 2003, The American journal of cardiology.

[36]  P. Ferdinandy,et al.  Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. , 2003, Cardiovascular research.

[37]  L. Kritharides,et al.  Type of liver dysfunction in heart failure and its relation to the severity of tricuspid regurgitation. , 2002, The American journal of cardiology.

[38]  S. Anker,et al.  Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. , 2002, The American journal of cardiology.

[39]  S. Anker,et al.  Cachexia: a therapeutic approach beyond cytokine antagonism. , 2002, International journal of cardiology.

[40]  H. Karch,et al.  Saliva IgM and IgA Are a Sensitive Indicator of the Humoral Immune Response to Escherichia coli O157 Lipopolysaccharide in Children with Enteropathic Hemolytic Uremic Syndrome , 2002, Pediatric Research.

[41]  Rainer Hambrecht,et al.  Effects of Xanthine Oxidase Inhibition With Allopurinol on Endothelial Function and Peripheral Blood Flow in Hyperuricemic Patients With Chronic Heart Failure: Results From 2 Placebo-Controlled Studies , 2002, Circulation.

[42]  W. Kübler,et al.  Respiratory Muscle Dysfunction in Congestive Heart Failure: Clinical Correlation and Prognostic Significance , 2001, Circulation.

[43]  Anita Deswal,et al.  Cytokines and Cytokine Receptors in Advanced Heart Failure: An Analysis of the Cytokine Database from the Vesnarinone Trial (VEST) , 2001, Circulation.

[44]  U. Müller-Werdan,et al.  Zytokine bei Herzerkrankungen , 2001, Der Internist.

[45]  S. Anker,et al.  Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure , 2000, Circulation.

[46]  F. Alla,et al.  Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES) , 2000, Circulation.

[47]  D. Rockey,et al.  Ischemic hepatitis: clinical presentation and pathogenesis. , 2000, The American journal of medicine.

[48]  K. Werdan,et al.  Immune Modulation by Catecholamines – a Potential Mechanism of Cytokine Release in Heart Failure? , 2000, Herz.

[49]  J E Parrillo,et al.  Myocardial dysfunction in septic shock. , 2000, Critical care clinics.

[50]  W. Langhans,et al.  Interleukins and tumor necrosis factor as inhibitors of food intake , 1999, Neuropeptides.

[51]  A. Harken,et al.  Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. , 1999, Critical care medicine.

[52]  Josef Niebauer,et al.  Endotoxin and immune activation in chronic heart failure: a prospective cohort study , 1999, The Lancet.

[53]  P. Ponikowski,et al.  Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. , 1999, European heart journal.

[54]  G. Schuler,et al.  Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. , 1999, Journal of the American College of Cardiology.

[55]  K. Werdan,et al.  Cardiodepression by tumor necrosis factor-alpha. , 1999, European cytokine network.

[56]  S. Saip,et al.  Corticosteroid therapy augments gastroduodenal permeability to sucrose , 1998, American Journal of Gastroenterology.

[57]  Parker Mm Pathophysiology of cardiovascular dysfunction in septic shock. , 1998 .

[58]  H. Volk,et al.  Systemic inflammation in patients with heart failure. , 1998, European heart journal.

[59]  W. Paulus,et al.  Pro-inflammatory cytokines and endothelium-dependent vasodilation in the forearm. Serial assessment in patients with congestive heart failure. , 1998, European heart journal.

[60]  D. Meldrum Tumor necrosis factor in the heart. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.

[61]  P. Poole‐Wilson,et al.  Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure. , 1998, QJM : monthly journal of the Association of Physicians.

[62]  T. Kirchgessner,et al.  Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. , 1997, The Journal of clinical investigation.

[63]  S. Anker,et al.  Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. , 1997, Journal of the American College of Cardiology.

[64]  P. Ponikowski,et al.  Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. , 1997, Circulation.

[65]  P. Poole‐Wilson,et al.  Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. , 1997, The American journal of cardiology.

[66]  D. Mann,et al.  The role of cytokines in disease progression in heart failure. , 1997, Current opinion in cardiology.

[67]  P. Ponikowski,et al.  Wasting as independent risk factor for mortality in chronic heart failure , 1997, The Lancet.

[68]  M. Entman,et al.  Tumor Necrosis Factor-α Provokes a Hypertrophic Growth Response in Adult Cardiac Myocytes , 1997 .

[69]  J. Schaper,et al.  Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. , 1997, European heart journal.

[70]  D. Zechner,et al.  Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. , 1996, The Journal of clinical investigation.

[71]  J. Takala Determinants of splanchnic blood flow. , 1996, British journal of anaesthesia.

[72]  D. King,et al.  Fat malabsorption in elderly patients with cardiac cachexia. , 1996, Age and ageing.

[73]  O. Febo,et al.  Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. , 1995, Circulation.

[74]  R. Dantzer,et al.  Compared effects of cold ambient temperature and cytokines on macronutrient intake in rats , 1995, Physiology & Behavior.

[75]  R. Beale,et al.  Assessment of splanchnic oxygenation by gastric tonometry in patients with acute circulatory failure. , 1993, JAMA.

[76]  J. Bland,et al.  Comparison of clinical information gained from routine blood-gas analysis and from gastric tonometry for intramural pH , 1993, The Lancet.

[77]  C. Roussos,et al.  Chemical activation of thin-fiber phrenic afferents. 2. Cardiovascular responses. , 1991, Journal of applied physiology.

[78]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[79]  Y. Shibayama Enhanced hepatotoxicity of endotoxin by hypoxia. , 1987, Pathology, Research and Practice.

[80]  Y. Shibayama The role of hepatic venous congestion and endotoxaemia in the production of fulminant hepatic failure secondary to congestive heart failure , 1987, The Journal of pathology.

[81]  L. Hanson,et al.  Appearance of secretory IgM and IgA antibodies to Escherichia coli in saliva during early infancy and childhood. , 1984, The Journal of pediatrics.

[82]  W. A. Day,et al.  High perfusion pressure damages the sieving ability of sinusoidal endothelium in rat livers. , 1980, British journal of experimental pathology.

[83]  T. Newby,et al.  Antibody Response of the Lactating Sow to Oral Immunization with Escherichia coli , 1980, Scandinavian journal of immunology.

[84]  M. Langman,et al.  GASTRIC AND DUODENAL ULCER AND THEIR ASSOCIATED DISEASES , 1976, The Lancet.